BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aria Biosystems Corporation Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal Test(TM) - and Publication of Study on Specimen Transport


2/7/2012 8:33:05 AM

SAN JOSE, Calif., Feb. 6, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, today announced that its new prenatal test has been named the Harmony Prenatal Test. The test is a directed non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood to detect common trisomies linked to genetic disorders.

(Logo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO )

"The name perfectly describes Aria's goal of bringing harmony to patients, medical service providers and healthcare networks by offering an advanced prenatal test that is highly accurate, accessible and affordable to a broad population," said Todd Whitson, vice president of sales and commercial operations at Aria Diagnostics. "The current landscape of prenatal testing can be cumbersome and confusing. We hope to streamline the process by providing this simple blood test."

The Harmony Prenatal Test utilizes new technology which couples innovative biochemistry, DANSR, and a proprietary algorithm, FORTE, to efficiently analyze patients' blood samples.

The company also announces the publication of a study on the effects of temperature during shipping of blood specimens. The article titled, "Influence of Temperature during Transportation on Cell-Free DNA Analysis" is published online in the journal Fetal Diagnosis and Therapy and available at http://content.karger.com/produktedb/produkte.asp?DOI=000335020. This publication follows several recent data announcements, including the peer-reviewed journal publication of three clinical studies in more than 1,000 patients and the launch of a large scale clinical trial comparing the Harmony Prenatal Test with the standard first-trimester screening test in 25,000 women.

The company will be exhibiting information about the Harmony Prenatal Test and its proprietary technology approach at the Society for Maternal Fetal Medicine's 32nd Annual Meeting in Dallas, TX, Feb. 8-11.

About Aria Diagnostics

Aria Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Aria is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Aria's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariadx.com.

SOURCE Aria Diagnostics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES